Counterpoint: Prevention of Cytomegalovirus (CMV) Infection and CMV Disease in Recipients of Solid Organ Transplants: The Case for Prophylaxis.
In: Clinical Infectious Diseases, Jg. 40 (2005-03-01), Heft 5, S. 709-712
Online
academicJournal
Zugriff:
This article presents information on the prevention of cytomegalovirus (CMV) infection and CMV disease in recipients of solid organ transplants. Outside of improvements in immunosuppressive therapy, the control of cytomegalovirus (CMV) infection in solid organ transplantation has been considered as the most significant advance in organ transplantation to have taken place in the past 20 years. As a result of prevention of CMV infection, both the direct and the indirect effects secondary to CMV replication have led to improved outcomes. The ideal prophylactic agent should be one that is highly effective, nontoxic, easily administered, and inexpensive. Unfortunately, valganciclovir or ganciclovir, although highly effective for preventing CMV replication, are not ideal agents. These drugs are very expensive and potentially toxic.
Titel: |
Counterpoint: Prevention of Cytomegalovirus (CMV) Infection and CMV Disease in Recipients of Solid Organ Transplants: The Case for Prophylaxis.
|
---|---|
Autor/in / Beteiligte Person: | Snydman, David R. |
Link: | |
Zeitschrift: | Clinical Infectious Diseases, Jg. 40 (2005-03-01), Heft 5, S. 709-712 |
Veröffentlichung: | 2005 |
Medientyp: | academicJournal |
ISSN: | 1058-4838 (print) |
DOI: | 10.1086/427509 |
Schlagwort: |
|
Sonstiges: |
|